Abstract
Objective
To discuss the use of melatonin as an early treatment option on the first day of diagnosis for COVID-19.
Methods
Medical Subject Headings terms “COVID-19” and “viral diseases” were manually searched on PubMed, and relevant articles were included.
Results
The results showed that melatonin acts to reduce reactive oxygen species–mediated damage, cytokine-induced inflammation, and lymphopenia in viral diseases similar to COVID-19.
Conclusion
These conclusions provide evidence for potential benefits in melatonin use for COVID-19 treatment as early as the day of diagnosis.
All Keywords
【저자키워드】 COVID-19, SARS-CoV-2, melatonin, antioxidant, Viral diseases, anti-inflammatory agent, 【초록키워드】 Treatment, Inflammation, Diagnosis, lymphopenia, early treatment, disease, Evidence, medical subject heading, article, objective, reactive oxygen, Result, searched, in viral, potential benefit, reduce, 【제목키워드】 review, narrative, current,
【저자키워드】 COVID-19, SARS-CoV-2, melatonin, antioxidant, Viral diseases, anti-inflammatory agent, 【초록키워드】 Treatment, Inflammation, Diagnosis, lymphopenia, early treatment, disease, Evidence, medical subject heading, article, objective, reactive oxygen, Result, searched, in viral, potential benefit, reduce, 【제목키워드】 review, narrative, current,